SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS OF BIOSPECIFICS TECHNOLOGIES CORP. ARE URGED
TO READ CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION SUCH HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. The tender offer materials and the Solicitation/Recommendation
Statement will be made available for free at the SECs website at www.sec.gov. Copies of the documents filed with the SEC by Parent and Purchaser will be available free of charge on Endos website. In addition, security holders of the
Company may obtain free copies of the tender offer materials by contacting the information agent for the Offer that will be named in the Tender Offer Statement on Schedule TO. Copies of the documents filed with the SEC by the Company will be
available free of charge on BioSpecifics Technologies Corp.s website.
Forward Looking Statement
This communication contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian
securities legislation. Statements including words such as believes, expects, anticipates, intends, estimates, plan, will, may, look forward,
intend, guidance, future or similar expressions are forward-looking statements. These forward-looking statements include, among others, statements relating to Parents or the Companys future financial
performance, business prospects and strategy, including the Offer, the Merger, the ability to successfully complete such transactions and other similar matters. Actual results could differ materially from those contained in these forward-looking
statements for a variety of reasons, including, among others, the risks and uncertainties inherent in the Offer and the Merger, including, among other things, regarding how many of the Companys stockholders will tender their shares in the
Offer, the possibility that competing offers will be made, the ability to obtain requisite regulatory approvals relating to the acquisition, the ability to satisfy the conditions to the closing of the Offer and the Merger, the expected timing of the
Offer and the Merger, the risk of stockholder litigation relating to the transaction, including resulting expense or delay, difficulties or unanticipated expenses in connection with integrating the Companys operations into Parents and
the possibility that anticipated synergies and other benefits of the transaction will not be realized in the amounts anticipated, within the expected timeframe or at all, the effect of the announcement of the Offer and the Merger on Parents
and the Companys business relationships, competition, including technological advances, new products and patents attained by competitors, challenges to patents, the occurrence of any event, change or other circumstances that could give rise to
the termination of the Merger Agreement, the expected tax treatment of the transaction, challenges inherent in product research and development, clinical trial outcomes and quality, availability and affordability of products, and other circumstances
beyond Parents and the Companys control. You should not place undue reliance on these forward looking statements. Certain of these and other risks and uncertainties are discussed in Parents and the Companys filings with the
SEC and, in Parents case, with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval, including the Schedule TO (including the offer to purchase, letter of transmittal and related documents) Parent and
Purchaser will file with the SEC, the Solicitation/Recommendation Statement on Schedule 14D-9 that the Company will file with the SEC and their respective Form
10-Ks and 10-Qs under the caption Risk Factors and as otherwise enumerated therein. Parent assumes no obligation to publicly update any
forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws.
EXHIBIT INDEX